Biohaven (BHVN) Financials: Revenue & Earnings
BHVN$16.20+0.68 +4.38%
$2.45B
Market Cap
-3.34
P/E
16.61
Forward P/E
53
Score
Biohaven (BHVN) Financials: Revenue & Earnings
BHVN price $16.20 +0.68 +4.38%
- Ticker
- BHVN
- Price
- $16.20
- Change
- +0.68 +4.38%
- Market cap ?
- $2.45B
- P/E ?
- -3.34
- Forward P/E ?
- 16.61
- Dividend yield ?
- 0.00%
- Beta ?
- 3.20
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 53
- Value
- 50
- Quality
- 27
- Growth
- 82
Stocklytics score rationale: value 50, quality 27, growth 82.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial…
Earnings and financials
Biohaven Ltd. (BHVN) trades at $16.20, with a market cap of $2.45B and a trailing P/E of -3.34. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insights · Dividends · Forecast · Financials · Learn